NIH Study Suggests That 200 mg Is The Optimal Daily Dose of Vitamin C

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

BETHESDA, Md--Although only 10 mg/day of vitamin C is enough to prevent deficiency, the optimal daily intake is probably 200 mg, according to results of a new NIH-sponsored study. The current Recommended Dietary Allowance (RDA) is 60 mg.

BETHESDA, Md--Although only 10 mg/day of vitamin C is enough toprevent deficiency, the optimal daily intake is probably 200 mg,according to results of a new NIH-sponsored study. The currentRecommended Dietary Allowance (RDA) is 60 mg.

In this study, vitamin C was given in various amounts to sevenhealthy young male volunteers who lived in a hospital ward forthe duration of the study so that intake could be strictly controlled.The NIH researchers, led by Dr. Mark Levine, found that the 200mg level was best absorbed by the body; absorption levels fellas the dose was raised above 200 mg.

Daily doses higher than 400 mg offer no additional value, Dr.Levine said, since, at that level, a large amount of the doseis excreted from the body. The research also suggests that veryhigh doses could be dangerous: At 1,000 mg/day, the urine wasfound to contain oxalate, a breakdown product of the vitamin thatcould lead to kidney stone formation in some people.

Recent Videos
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
Related Content